In this article, Dr Jaime Shamonki, Generate Life Science’s CMO, discusses how newborn stem cells derived from umbilical cord tissue could make mesenchymal stem cells less expensive and variable to produce.
Mesenchymal stem cells (MSCs) are emerging as an important biological therapy and are being evaluated in a range of clinical indications. Found in tissues such as the bone marrow and the umbilical cord, these multipotent stem cells can produce and repair a variety of tissue cell types, including cartilage and bone.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
“While they were originally considered for regenerative medicine due to their ability to differentiate into the various types of mesenchymal tissue, we now understand that MSCs have an interesting ability to modulate the endogenous tissue through cell signalling and other pathways, rather than just contributing new biomass,” explained Dr Jaime Shamonki, the Chief Medical Officer of Generate Life Sciences. “For these reasons MSCs are currently being tested as a therapeutic for a variety of immune-mediated diseases, a category that is constantly expanding as we learn that many more diseases have an immune dysregulation or chronic inflammatory component than we appreciated in the past. Aside from the obvious applications in autoimmunity, MSCs are also being explored as therapeutics for graft versus host disease, cancer and some neurodegenerative conditions, like multiple sclerosis and Alzheimer’s.”
MSC therapies and COVID-19
More recently MSC therapies have been leveraged against COVID-19 because it is thought that the severest symptoms, such as Acute Respiratory Distress Syndrome (ARDS) and organ failure, are driven by immune dysregulation, resulting in cytokine storms.
Dr Shamonki said: “We have multiple lines of evidence that pre-date COVID-19 that show that MSCs are capable of reducing immune-mediated lung injuries by modulating inflammation and stimulating repair. Unlike the broad anti-inflammatory approach using pharmaceuticals such as corticosteroids, we know that MSCs interact with tissues in a more precise and co-ordinated manner. Effectively, they can re-balance the immune response by upregulating anti-inflammatory cytokines and down-regulating pro-inflammatory cytokines.
“Based on all the pre-clinical and clinical trial evidence, a research group in China had the idea of using MSCs in COVID-19 patients back in March. Many other similar studies have followed and now there are some early reports from clinical trials suggesting that treating patients with severe COVID-19 respiratory symptoms in this way results in some improvement. Mesoblast for example, reported a survival rate of 75 percent for patients on a ventilator treated with their MSC therapy, remestemcel-L, versus their control group (no MSC therapy) with around 15 percent.”
MSC collection and production
MSCs can be directly collected from the bone marrow of patients; however, this requires a painful procedure with the potential for complications and only produces a limited number of MSCs, many of which may not be able to self-replicate. As MSC precursors only account for about 0.001 to 0.01 percent of the overall cell population, each bone marrow sample only provides 60 to 600 cells per millilitre. As a result, a large amount of bone marrow samples and extensive ex vivo culturing is required to produce sufficient cell numbers for clinical applications in humans. All these factors make bone marrow-derived MSCs (BM-MSCs) somewhat impractical for the large-scale manufacture of MSCs for therapies.1
A number of other human tissues have been identified as alternative sources of MSCs, including adipose tissue, perinatal tissue, dental tissue and endometrial blood.1 Some suggest that adipose tissue-derived MSCs (AT-MSCs) may be a highly promising alternative to BM-MSCs, due to their relative ease of collection (using less invasive methods, such as liposuction), better yield (containing roughly 500 times more MSC precursors than bone marrow) and proliferation capacity, resulting in shorter expansion times.1 However, Dr Shamonki also suggests that newborn stem cells (those from the perinatal tissue) could also be a great source of MSCs with several advantages over other sources.
Newborn stem cells
Umbilical cord tissue contains MSCs and umbilical cord blood contains both haematopoietic stem cells (those able to produce blood cells) and MSCs. Both the cord blood and tissue can be collected through simple processes during birth, stored and later expanded to make lines of induced pluripotent stem cells (iPSCs) or substantial quantities of MSCs for use in therapies.
Dr Shamonki said that despite umbilical cord blood banking beginning in 1977, both blood and cord banking is still not widely practised: “In the US we have roughly 3.5 million births a year, but only five percent of the population banks the newborn stem cells. Umbilical cord blood and tissues are a valuable biological resource that is easy to collect, could have vital uses for either personalised therapeutics directly for the donor later in life or applications more widely in industry and yet is not being tapped.”
Comparing newborn and other stem cell types
One of the major advantages of newborn stem cells, according to Dr Shamonki, is the ease with which they can be collected and preserved: “Collecting the blood and tissues is the easiest thing in the world. For the blood, we canulate the umbilical vein and drain the blood into an anticoagulant formula in a bag. Collecting the cord tissue is even more simple; we cut a piece of the umbilical cord which can then be further segmented and cleaned up before it is cryogenically frozen in composite segments”.
Dr Shamonki said that quickly freezing the newborn stem cells after collection allows for the growth of relatively homogeneous populations of MSCs when the tissue is explanted (defrosted and punch biopsies placed on a plate to grow into cultures). Once these cultures have been established, the team performs screening for maternal infections and metabolic assays to ascertain which samples are likely to demonstrate healthy growth dynamics, selecting only the best cells to be sent for expansion by industry. She added that “the MSCs produced from umbilical tissue meet all the industry standard characteristics and clinical characteristics of MSCs” and that they have an incredible expansion capacity, often above and beyond that of adult-derived BM-MSCs.
Dr Shamonki also revealed that newborn stem cells have donor advantages: “Variability from one lot to the next is the bane of manufacturing, particularly when working with live cells. Umbilical cord blood- and tissue-derived stem cells are less variable simply because newborn babies have not been exposed to many stressors, like mutagens or pathogens. As a result, when these cells are expanded into cell lines, the tissues are generally more homogeneous. The older a donor is, the more variability there is in the cells that they donate. This increases the potential that they have undesirable characteristics, so collecting younger cells with a lower lifetime exposure is advantageous.”
Newborn stem cells for immunotherapies
Generate recently began a collaboration with NantKwest, a company focused on the development of cancer immunotherapies. NantKwest has adapted its process for producing natural killer (NK) cells targeting specific cancers to develop a stem cell therapeutic for COVID-19 using BM-MSCs. Dr Shamonki explained that the two companies decided to expand the scope of that initiative by utilising umbilical cord MSCs as source material for the biologic therapy.
For this collaboration, Generate provides an intermediate product derived from umbilical cord MSCs that can be frozen and stored for cell expansion on demand. Dr Shamonki commented: “This is the first time that previously cryopreserved composite umbilical cord tissue has been successfully explanted and used to generate a product which is ready for expansion on demand and demonstrate that, not only does it perform really well in that expansion environment, but it also meets all of the criteria for MSCs. It was a really important proof-of-concept.”
Future applications of MSC therapies
“I believe we are in a really interesting place with MSCs. With an increasing number of trials focused on these therapies, we have gone from saying that MSCs may be used to regenerate certain tissues in the laboratory to instead saying that regenerative medicine comprises an expanding category of personalised therapeutics that include immuno-, cell and gene therapies. MSCs are among these, defining the future of precision and personalised medicine. In 10 years’ time, we could have a range of allogeneic off-the-shelf or directed therapies specifically tailored for an individual that we would never have dreamed of a decade ago.”
Dr Shamonki said that one of the interesting things about expanding the use of MSCs, especially into diseases such as COVID-19 which have a diverse range of symptoms and associated pathologies, is that we are constantly learning more about the mechanisms that underpin immune dysregulation, and that these discoveries go on to inspire additional studies and indications: “Despite what we are taught – those straightforward diagrams of immune or hormone regulation where point A goes to point B goes to point C – we never truly understand what is going on at a sub-cellular level. Using MSCs against heterogeneous diseases is both important for patients and exciting for researchers, because we can get a better understanding of what is really going on in that sub-cellular inflammatory environment in individual cases.”
Conclusions
So, could newborn stem cells revolutionise MSC therapies? Their advantages – including abundance, ease of collection, expansion capacity and the relative homogeneity of products they can produce – certainly make them a more attractive option than BM-MSCs for the large-scale production of cells for therapies, according to Dr Shamonki.
As for the potential uses of MSCs in clinic, it seems this is only growing, as both the number of conditions thought to have an underlying immune dysregulation component increases and their use further advances our knowledge of immune dysregulation and the ways MSCs can combat it.
Dr Jaime Shamonki is the Chief Medical Officer at Generate Life Sciences. She trained in Anatomic and Clinical Pathology at New York Presbyterian Hospital – Weill Cornell Medical College and has completed fellowships at Weill Cornell as well as the University of California, Los Angeles.
Prior to joining Generate, Dr Shamonki developed expertise in women’s health and clinical laboratory medicine, serving as the Director of Breast Pathology and Blood Bank Medical Director at Saint John’s Health Center in Santa Monica, US, and as an Assistant Professor at the John Wayne Cancer Institute.
Reference
Mastrolia, I., Foppiani, E.M., Murgia, A., et al.Challenges in Clinical Development of Mesenchymal Stromal/Stem Cells: Concise Review. 2019. STEM CELLS Translational Medicine, 8: 1135-1148. https://doi.org/10.1002/sctm.19-0044
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.